Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for treatment of some malignant and non-malignant hematological diseases. However, post-HSCT patients are severely immunocompromised and susceptible to viral infections, which are a major cause of morbidity and mortality. Although antiviral agents are now available for most types of viral infections, they are not devoid of side effects and their efficacy is limited when there is no concomitant antiviral immune reconstitution. In recent decades, adoptive transfer of viral-specific T cells (VSTs) became an alternative treatment for viral infection after HSCT. However, two major issues are concerned in VST transfer: the risk of GVHD and antiviral efficacy. We report an exhaustive review of the published studies that focus on prophylactic and/or curative therapy by donor VST transfer for post-HSCT common viral infections. A low incidence of GVHD and a good antiviral efficacy was observed after adoptive transfer of VSTs from HSCT donor. Viral-specific T-cell transfer is a promising approach for a broad clinical application. Nevertheless, a randomized controlled study in a large cohort of patients comparing antiviral treatment alone to antiviral treatment combined with VSTs is still needed to demonstrate efficacy and safety.
INTRODUCTION
Viral infections are important causes of morbidity and mortality after hematopoietic stem cell transplantation (HSCT). Although antiviral agents are now available for most types of viral infections, they are not devoid of side effects and their efficacy is sometimes limited in the absence of concomitant antiviral immune reconstitution. 1 A promising alternative consists of reconstituting the patient's specific antiviral immunity with virus-specific T cells (VSTs), 2, 3 either produced by ex vivo expansion 4 within 2-8 weeks or isolated by rapid immunomagnetic selection based on multimers 5 or IFNγ-capture system 6 in less than 48 h ( Figure 1 ). O'Reilly et al. 7 have recently published a review on VST banking established from third party donors. Consequently, in the following review, we mainly focused on VSTs from original HSCT donors reporting cumulative results, both in terms of efficacy and GVHD incidence, of a substantial number of published studies.
INFUSION OF EX VIVO EXPANDED VIRUS-SPECIFIC T CELLS
The recovery of virus-specific T-cell immunity is crucial for patients after HSCT to avoid viral infections or reactivations. Based on donor lymphocyte infusion experiments, 4, 6, 8 ex vivo expanded virus-specific T cells were developed reducing drastically the number of alloreactive T cells.
CMV-VSTs
Different groups generated CMV-specific T cells using peripheralblood mononuclear cells (PBMCs) from the HSCT donors co-cultured with different CMV-related stimulators such as autologous fibroblasts infected with the CMV AD169 strain, 8 PBMCs loaded with CMV lysate, 9 ,10 dendritic cells transfected with Ad5f35pp65 or pulsed with CMV antigen [11] [12] [13] [14] [15] [16] or CMV peptide mixes derived from full-length pp65 and/or IE1. 17 Altogether, 47 post-HSCT patients received adoptive CMV-specific T-cell (CMV-VST) infusions (range from 10 5 to 3 × 10 6 /kg or 0.06 to 100 × 10 7 /m 2 ) to treat CMV infections or diseases refractory to antiviral drugs (acyclovir, foscarnet, cidofovir or ganciclovir) 4 to 479 days following HSCT (Table 1) . Forty patients (85.1%) presented a complete clearance of CMV load in peripheral blood after one or two CMV-VST infusions, including 20 patients who did not receive any antiviral drug after CMV-VST infusion. Three of 47 patients (6.4%) presented grade I cutaneous GVHD post CMV-VST infusion, including 2 patients (4.2%) with de novo GVHD. Moreover, 110 post-HSCT patients received CMV-VSTs (range 10 5 to 3 × 10 6 /kg or 0.06 to 100 × 10 7 /m 2 ) as a prophylaxis 28 to 115 days following HSCT. 8, 10, 12, 13, 15 Eighteen patients (16%) presented CMV reactivations post CMV-VST infusion including five patients (4.5%) with CMV diseases. GVHD I to IV was observed in 18 patients (16%) post CMV-VST infusion. Interestingly, two teams compared the incidence of CMV reactivations or diseases in the patients who received prophylactic CMV-VSTs and in control cohorts. 10, 15 Incidence of CMV reactivations was of 16% (12/75 patients) in the prophylactic group and of 66% in the control cohorts (107/161 patients). Moreover, one of the two teams compared the incidence of aGVHD and cGVHD between the patients receiving prophylactic CMV-VST (n = 50) and control cohorts (n = 128) and no significant difference was observed.
EBV-VSTs
Five studies 4, [18] [19] [20] [21] reported EBV-VSTs generated from PBMC from HSCT donors stimulated with the autologous EBV-lymphoblastoid cell line. Altogether, 141 patients received EBV-VSTs after HSCT (range from 0.5 to 1 × 10 6 /kg or 1 to 5 × 10 7 /m 2 ). One hundred and one of 141 patients received EBV-VSTs to prevent EBV-related lymphoproliferative disease (EBV-PTLD) as prophylaxis 4 (Table 1) . No patient developed EBV-PTLD up to 15 years of follow-up although they had risk factors that included T-cell depletion or primary immunodeficiency. Forty other patients received EBV-VSTs as curative treatment for proven EBV-PTLD or detectable EBV viral load in peripheral blood resistant to conventional treatment like rituximab, chemotherapy or antiviral drugs. Thirty-one patients (77.5%) achieved CR. All of the responders presented an increase in EBV-VST quantification in blood concomitant with a decrease in EBV viremia and resolution of EBV-PTLD.
No immediate adverse reaction or de novo GVHD was observed in 141 patients after receiving EBV-VSTs from the HSCT donors. Eight patients (5.7%) had a recurrence of GVHD (6 patients in grade I, 2 patients in grade II) and 13 patients (9.2%) developed a cGVHD resolutive under treatment. These low cumulative incidences of both recurrent GVHD and chronic GVHD account for the safety of EBV-VST infusion.
ADV-VSTs
One study reported a generation of ADV-VSTs by short-term (12 days) ex vivo expansion of HSCT donor-derived PBMCs stimulated by overlapping ADV peptides in the presence of IL-15. 22 Two patients post-HSCT received ADV-VSTs (1 × 10 4 /kg) for the treatment of refractory ADV infection. One patient achieved CR without GVHD while the other one died of organ failure associated with ADV disease and GVHD although he experienced a transient reduction of ADV load over 1.5 log after ADV-VST infusion.
Multiple-VSTs
More recently, some investigators generated multiple-VSTs using PBMCs from the HSCT donors co-cultured with different viralrelated stimulators, including two-virus-STs 23 ) as a curative treatment of one to four viral infections/diseases (n = 29) or as a prophylaxis (n = 13).
Among the 29 patients with curative VST-treatment, 26 patients (89.7%) presented CR (n = 24) or PR (n = 2) of all the viral infections or diseases including three patients with EBV-PTLD (Table 1) . For the 13 patients with prophylactic VST-treatment, seven patients did not experience relative viral infections up to 3 months after four-virus-ST infusion and six patients developed CMV reactivation but not the other relative viral infections after infusion during 12-month follow-up.
Five among 42 patients (11.9%) presented GVHD II-IV after multiple-VST infusion including one de novo GVHD II.
VSTs from third party donors Several studies reported the generation of VSTs (CMV-VSTs 7 EBVVSTs, 7,21,27-31 multiple-VSTs 32 ) from unrelated third party donors by ex vivo expansion. One hundred and thirty-nine patients received VSTs (range from 1 to 5 × 10 6 /kg or 2 × 10 7 /m 2 ) for the treatment of refractory EBV-PTLD or viral infections. Ninety-two of 134 evaluable patients (68.7%) achieved CR (n = 55) or PR (n = 37). In 70 evaluable patients for GVHD, 2 presented de novo GVHD (2.7%) and 6 had reactivation of GVHD I (n = 4) and GVHD II (n = 2).
INFUSION OF FRESHLY AND RAPIDLY ISOLATED VSTS
As traditional ex vivo expanded VSTs require a long generation time (between 10 days to 1 month), patients with acute viral reactions cannot receive VSTs unless they were prepared for each patient before HSCT, which is a brake to the diffusion of this technique. In addition, technically demanding protocols also limit the broad clinical implementation of this method. VST banking should be a good way to rapidly obtain off-the-shelf VSTs ready for clinical infusion, but the culture process remains timeconsuming and cost-intensive mainly to establish a large number of VST lines covering most of HLA types including the rarer. 7 An alternative method has also been developed to freshly isolate VSTs from a leukapheresis by an immunomagnetic strategy using HLA-peptide multimers 5 or IFNγ-capture system. 6 This
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Viral specific T cell therapy for post HSCT viral infection C Qian et al method is faster (24-48 h), easier and less expensive for broad clinical implementation.
VIRUS-SPECIFIC T CELLS BY HLA-PEPTIDE MULTIMERS CMV-VSTs
To our knowledge, three investigators 5, [33] [34] [35] reported the treatment of post-HSCT CMV infection using adoptive transfer of fresh CMV-specific CD8 + T cells generated by an immunomagnetic strategy based on HLA-peptide multimers from HSCT donors. Twenty-one patients received CMV-specific CD8 + T cells (dose range from 0.78 to 285 × 10 3 /kg) for treatment of CMV infections refractory to antiviral drugs. All of the 20 evaluable patients achieved CR (n = 17) or PR (n = 3) ( Table 2 ). Four patients had aGHVD I-III (n = 3) or cGVHD (n = 1) within 1 month of CMV-VST infusion. However, three of them had developed previous GVHD before infusion, the remaining one had received a natural killer cell transfusion and an unselected donor lymphocyte infusions at 21 and 8 days before CMV-VST infusion, respectively.
Multimers are most readily made with class I HLA and can only select CD8+ T cells but not the CD4+ T-cell subset restricted by class II HLA. 36 In some viral infections, for example ADV infection, immune response is mainly supported by CD4+T cells. 6, 37 Moreover CD4+ T cells are necessary to support in vivo expansion and survival of CD8+ T cells 4, 38 to maintain virus-specific immune response following adoptive transfer for a long time. In contrast, IFNγ-capture approach can select both CD4+ and CD8+ antigenspecific T cells in an HLA unrestricted manner.
VIRUS-SPECIFIC T CELLS IFNΓ-CAPTURE SYSTEM
Recovered peripheral blood mononuclear cells (PBMCs) are stimulated for 6-16 h with a viral antigen. 6, [39] [40] [41] [42] These cells are subsequently processed using the Cytokine Capture System (CCS; Miltenyi Biotec) based on an IFN-γ immunomagnetic technology on the CliniMACS device (Miltenyi Biotec), as previously described. 43, 44 This technique can rapidly isolate multi-clone VSTs including CD4+ and CD8+ cells.
CMV-VSTs
Three investigators generated CMV-VSTs using immunomagnetic isolation based on IFNγ-capture system from PBMC of HSCT donors stimulated ex vivo with pp65 protein 42 or a pool of CMVpp65 peptides. 42, 45, 46 Forty-six patients received CMV-VSTs post HSCT for prophylaxis 42 (n = 7), preemptive treatment 42 (n = 11) or curative treatment of CMV infection refractory to antiviral drugs 45, 46 (n = 28) ( Table 2 ). The infused dose of CMV-VST CD4+ cells ranged from 0.28 to 61.4 × 10 3 cells/kg and CMV-VST CD8+ cells ranged from 0.06 to 20.1 10 3 × cells/kg. In the prophylaxis study, no patient required antiviral therapy within the next 6 months and no CMV disease was observed in any patient. In the preemptive study, antiviral treatment was reduced in 9/11 patients and not required in 2 patients. In the cohort of patients treated for CMV infection refractory to antiviral drugs, 15 among 25 evaluable patients (60%) presented a clearance (n = 12) or a significant decrease (41log) (n = 3) of CMV viremia including 2 cases of CMV encephalitis. Interestingly, it was suggested that efficacy of VST transfer was not related to the T-cell dose as even a very small dose of 360 CD3+ cells/kg was shown to generate successful antiviral response. 45 Five patients experienced GVHD I (10.9%) and four, GVHD II-III (8.7%).
EBV-VSTs
Two studies reported the generation of EBV-VSTs using immunomagnetic isolation based on IFNγ-capture system from PBMC of 
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HSCT donors stimulated ex vivo with one or a pool of EBV peptides. Icheva et al. 47 isolated EBV-VSTs from PBMC of HSCT donors stimulated with EBV nuclear antigen 1 (EBNA-1) protein (n = 7) or EBNA-1 Peptivator (Miltenyi Biotec, n = 3), a pool of EBNA-1 peptides (Table 2 ). Ten pediatric and adult patients with refractory EBV viremia (n = 2) or EBV-PTLD (n = 8) received EBV-VSTs after HSCT. The mean infused CD3 T-cell dose was 5.79 ± 12.83 × 10 3 /kg (range from 0.15 to 53.796 × 10 3 /kg), containing both CD4+ (54.5% ± 30%) and CD8+ (35.8 ± 30%) T cells. In vivo expansion of EBV-specific T cells was observed in eight patients (80%) and seven (70%) achieved clinical and viral responses. Six of eight (75%) patients with EBV-PTLD responded to EBV-VST infusion. One patient among two with advanced stage disease, presented a response to EBV-VST. One patient developed transient grade I to II acute skin GVHD at day 15 after EBV-VST infusion which was considered related to EBV-VST.
Moosmann et al. 41 produced EBV-specific T cells from PBMCs of HSCT donors stimulated with an EBV peptide pool 48, 49 (Table 2 ). Six patients who developed biopsy-proven EBV-positive PTLD after allo-HSCT received a single infusion of EBV-VST of 58 ± 38 × 10 3 /kg total viable cells including 4.2 ± 5.3 × 10 3 CD4+ cells/kg and 3.6 ± 5.9 × 10 3 CD8+ cells/kg. The six patients presented progressive disease during short-term (3-14 days) conventional therapy (antiviral drugs and rituximab). Three patients with early-stage PTLD had a rapid and CR after transfer of EBV-VST, and no GVHD was observed. However, three patients with late-stage PTLD with multiorgan dysfunction continued to have progressive disease and had weak or absent response after adoptive transfer.
ADV-VSTs
To our knowledge, the majority of ADV-VSTs were generated by immunomagnetic isolation based on IFNγ-capture system from PBMC of HSCT donors. PBMCs were stimulated ex vivo before isolation with ADV2 Hexon protein 6, 39, 50 or peptivator ADV5 Hexon peptide pool. 40, 46, 51 Fifty-five patients who had refractory ADV infections or diseases received ADV-VSTs at dose range from 0.25 to 28.1 × 10 3 CD3+T cells/kg (Table 2) . Both CD4+ and CD8+ T cells were detected after isolation and the CD4+ T cells were the major compartment in most of ADV-VSTs (mean from 63.2 to 72%) compared with CD8+T cells. In the 49 evaluable patients after ADV-VST infusion, 38 (77.6%) patients presented ADV viral load clearance (n = 34) or notable decrease (n = 4). One of them with severe ADV-related respiratory failure experienced clinical improvement with a clearance of ADV load after 20 days associated with ADV-VST reconstitution. 40 Eight patients (14.5%) presented GVHD after infusion of ADV-VSTs including two patients with GVHD I, five patients with GVHD II-III and one with extensive cGVHD.
BKV-VSTs
Recently, Pello et al. generated BKV-VST from HSCT donor by immunomagnetic isolation based on IFNγ-capture system using PepTivators BKV-LT and BKV-VP1 as stimulators. In one patient with refractory severe BKV hemorrhagic cystitis, resolution of both the symptoms and viremia was achieved after BKV-VST transfer without GVHD 52 (Table 2) .
VSTs from third party donors Several studies reported the generation of VSTs (CMV-VSTs, 34, 35 EBV-VSTs, 53 ADV-VSTs 34, 51 ) from third party donors using freshly and rapidly isolation by HLA-peptide multimers or IFNγ-capture system. Twenty-three patients received VSTs (from 1.1 to 246 × 10 3 CD3+ T cells/kg) for refractory viral infections including one EBVassociated lymphoma. Seventeen patients (73.9%) achieved CR (n = 14) or PR (n = 3). Two patients presented reactivation of GVHD I (n = 1) and GVHD II (n = 1).
CONCLUSION Viral-specific T-cell transfer generated from HSCT donor PBMCs for the treatment of post-HSCT viral infections or diseases is associated with a good antiviral efficacy and tolerance. Overall and regardless of the method used to generate VSTs, 91.3% patients achieved CR (73.8%) or PR (17.5%) among 229 evaluable patients receiving VSTs from HSCT donors, and 3 de novo GVHD (1.3%) and 17 GVHD reactivation (7.1%) occurred after VST infusion. Regarding the lower antiviral efficacy reported when VSTs were infused at late-stage of viral infections or diseases, 39, 41 we suggest that preemptive treatment should be considered in the future. Indeed, the Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines recommends that donor or third party EBV-VSTs should be considered for preemptive therapy of EBV disease. Moreover, EBV-VSTs are now recommended at a firstline therapy in EBV-PTLD. 54 The ex vivo expansion method could significantly enrich VSTs and expand them to a large cell number. However, this technique can hardly be broadly implemented. In the recent decade, freshly isolated VSTs presented safety and efficacy against post-HSCT viral infections. If the method of HLA-peptide multimers presents a limitation with a class I HLA-restriction allowing isolation of one CD8+ T-cell clone with a specificity limited to one peptide presented by one MHC molecule, the CCS (Miltenyi Biotec) based on an IFN-γ immunomagnetic technology isolates the functionally active T cells, making it possible to generate polyclonal CD4+ and CD8+ T cells. Moreover, the polyclonal VSTs are able to target most viral peptides presented by the patient HLA molecules enhancing anti-virus efficacy, provided that an antiviral-specific immune response is present in the donor. However, if the HSCT donor cannot be recruited again for VST preparation, due to an absence of specific immune response, to a refusal of the donor center in case of MUD donor, or because the graft was MUD UCB, a third party haploidentical donor can be contacted. Indeed, Qian et al. reported a series of six UCB transplanted patients who received ADV-VSTs from a third party haploidentical donor. In this study, no differences regarding intensity or persistence of ADVspecific immune response and ADV viral load clearance were observed between patients who received ADV-VSTs from HSCT original donors and from third party haploidentical donors. 51 Although, only 15 cases have been reported so far, an efficacy was observed for 80% of patients who achieved viral infection or disease remission. This type of donors presents theoretical advantages: rapidly available, a specific immune response which can be controlled before collection, a full HLA haplo-identity with the recipient and potentially with the HSCT graft, except maybe in case of UCB transplantation. The experience reported in the context of VST banking showed that, although a significantly better immune response is observed at 6 months when HLA matches are higher, 28 efficacy can still be observed even with a single HLA allele matched with the recipient. 32 However, we have succinctly analyzed here an exhaustive number of VST infusions generated from unrelated third party donors in the context of bank storage. Overall, we observed that 63.8% patients achieved CR (38.8%) or PR (25%) among 152 evaluable patients treated for viral infections or diseases. O'Reilly et al. 7 have recently reported similar results with a disease response rate ranging from 50 to 76%. In 88 evaluable patients for GVHD, 2 de novo GVHD (2.3%) and 6 reactivations of GVHD I-II (6.8%) occurred after VST infusion. Without comparing, it is nonetheless interesting to notice that efficacy seems different between VSTs from HSCT donors and unrelated third party donors (91.3% vs 64% CR and PR), while incidence of GVHD remains low. Unlike with the ex vivo expanded method, the number of isolated VSTs with the immunomagnetic technique is very low. Thus, efficacy of VSTs generated by immunomagnetic selection relies on their expansion potential. If the dose of infused cells was not reported critical for expansion, the composition of those cells may play an important role. 45, 51 Indeed, the presence of a pool of stem memory T cell (TSCM) might be essential for the control of persisting infections, as effector T cells undergoing functional exhaustion and replicative senescence need to be replenished continuously by less differentiated T-cell subsets. [55] [56] [57] [58] The mature subpopulations of VSTs may support the immediate cytotoxicity, while the immature subpopulations may play a crucial role in sustaining VST expansion in vivo and continuous anti-viral efficacy until patients present an immune reconstitution from the graft.
Expansion of immunomagnetic isolated VSTs also depends on the in vivo environment. Patients who need VST immunotherapy often present GVHD and/or receive immunosuppressive drugs which may impair VST expansion. Although the impact of immunosuppressive drugs on VST is poorly known, two studies compared anti-virus efficacy of VSTs in patients who received immunosuppressive drugs or not 21, 39 and reported that anti-virus efficacy of VSTs was not significantly different between the two groups. Actually, although some patients received steroids at a dose over 1 mg/kg, they achieved a viral clearance associated with an in vivo expansion of VSTs. 39, 47 For example, in the clinical study we recently reported, four patients receiving steroids during ADV-VST therapy did not present any delay in ADV-specific immune reconstitution compared with the patients who did not receive steroids. 51 On the other hand, GVHD reactivation was mainly observed in patients whose immunosuppressive treatment was decreased before or at the time of VST infusion. In the absence of evidence of a clear impact of immunosuppressive drugs (except T-cell depleting antibodies) on VSTs, and considering that modulation of immunosuppression could secondarily increase the risk of GVHD reactivation, steroid immunosuppression should not be decreased under 1 mg/kg or even stopped before or at the time of VST infusion. Although gene modification of freshly isolated VSTs without an expansion culture step has not been reported yet, different interesting attempts have been made to generate resistance of culture-VSTs to different immunosuppressive drugs such as calcineurin inhibitors 59, 60 (tacrolimus and cyclosporin A) and glucocorticoid 61 by gene transfection technology. The immunosuppressive drug resistance did not impair functional properties of culture-VSTs or specific proliferation, IFN-γ secretion or cytotoxicity. This strategy, which provides a promising way to allow co-administration of immunosuppressive drugs and VSTs, needs now to be implemented to freshly isolated VSTs mostly if clinical studies confirm an impaired in vivo VST expansion in presence of immunosuppression.
A randomized, controlled study in a large cohort of patients comparing antiviral treatment alone to antiviral treatment combined with VSTs is required in order to confirm the safety and efficacy of VST infusion. Such a trial can only be conducted on a multicenter scale, at an international level, to allow a substantial inclusion rate. Indeed, a European academic multicenter trial, TRACE, coordinated par T Feuchtinger will be initiated in few months. By providing evidence of the safety of VST infusion, it will allow for a wide early implementation of this strategy leading to an improved management of viral infections or diseases. The easily standardized production process of immunomagnetic isolated VSTs will contribute to this dissemination.
